How Does Adlyxin (Lixisenatide) Work? Mechanism of Action Explained in Plain English

Adlyxin (lixisenatide) was a once-daily injectable GLP-1 receptor agonist for type 2 diabetes, discontinued in the US in January 2023. Understanding how lixisenatide worked matters today because its mechanism is shared with currently available GLP-1 medications — and because Soliqua 100/33, which still contains lixisenatide, remains on the market. This guide explains the science in plain language.

What Is a GLP-1 Receptor Agonist?

GLP-1 stands for glucagon-like peptide-1. It is a hormone naturally produced by specialized cells (L-cells) in your small intestine when you eat. GLP-1 plays a critical role in blood sugar regulation by signaling the pancreas to release insulin and suppressing glucagon release after meals.

The problem in type 2 diabetes is that the GLP-1 response is often impaired — people with T2D either don't produce enough GLP-1 or their pancreas doesn't respond to it well. GLP-1 receptor agonists like lixisenatide work by mimicking GLP-1 with a synthetic molecule that activates the same receptors, but lasts much longer in the body than the natural hormone (which breaks down within minutes).

How Lixisenatide Specifically Worked: The Three Mechanisms

Mechanism 1: Glucose-Dependent Insulin Release

When you eat, lixisenatide stimulated the beta cells of the pancreas to release more insulin — but only when blood glucose was already elevated. This 'glucose-dependent' mechanism is an important safety feature: because lixisenatide only triggered insulin release when blood sugar was high, it had a low risk of causing hypoglycemia (dangerously low blood sugar) on its own. This differs from sulfonylureas, which cause insulin release regardless of glucose level and carry higher hypoglycemia risk.

Mechanism 2: Glucagon Suppression

Glucagon is a hormone produced by alpha cells in the pancreas that raises blood sugar — it is essentially the opposite of insulin. In type 2 diabetes, glucagon levels are often inappropriately elevated after meals, contributing to high postprandial blood glucose. Lixisenatide suppressed glucagon secretion after meals, reducing this counterproductive blood sugar elevation.

Mechanism 3: Gastric Emptying Inhibition (Lixisenatide's Signature Effect)

This is where lixisenatide was truly distinctive compared to other GLP-1 agents. Lixisenatide powerfully slowed gastric emptying — the rate at which food leaves your stomach and enters the small intestine. By delaying gastric emptying, lixisenatide dramatically blunted the rise in blood glucose after meals (postprandial glucose spikes).

In clinical studies, lixisenatide reduced postprandial blood glucose by approximately 15.6 h·pmol/L (as measured by the area under the curve) compared to placebo after a standardized test meal. This was its strongest clinical differentiation from longer-acting GLP-1 agents. However, this same effect was also the primary cause of its GI side effects — slowing gastric emptying causes nausea, especially early in treatment.

What Makes Lixisenatide a 'Short-Acting' GLP-1?

GLP-1 receptor agonists are classified as short-acting (administered once or twice daily) and long-acting (administered once weekly). Lixisenatide was a short-acting agent — it reached peak concentration about 1–3.5 hours after injection and was cleared more rapidly than weekly agents. This pharmacokinetic profile meant:

Stronger postprandial glucose-lowering effect (vs long-acting GLP-1 agents, which reduce fasting glucose more)

Required once-daily administration timed to the first meal

Did not maintain consistent overnight or between-meal GLP-1 receptor stimulation like once-weekly agents

What Was Lixisenatide's Chemical Structure?

Lixisenatide is a 44-amino acid synthetic peptide, derived from exendin-4 (a compound found in Gila monster saliva). Like exenatide, it shares significant structural similarity with human GLP-1 but was modified at the C-terminus — with a deletion of one proline and the addition of six lysine residues. This modification gave it approximately four times greater affinity for the GLP-1 receptor than native human GLP-1 and approximately 55% plasma protein binding. Its molecular weight is 4,858.5 daltons.

How Does This Compare to Today's GLP-1 Medications?

All GLP-1 receptor agonists work through these same core mechanisms — but with meaningful differences in pharmacokinetics, potency, and effect profile. Long-acting agents like semaglutide and dulaglutide provide sustained GLP-1 receptor activation that reduces both fasting and postprandial glucose, along with stronger weight loss effects. Tirzepatide adds GIP receptor agonism (a separate incretin pathway), producing the strongest A1C and weight reduction in the class.

For a broader overview of what Adlyxin was as a product, see our Adlyxin Starter Kit guide. If you need help locating a GLP-1 alternative near you, medfinder calls pharmacies on your behalf to find which ones have your medication in stock.